Supplementary Material

Supplementary Table 1. ACMG/AMP criteria that were excluded from TP53-specific guidelines

Original ACMG/AMP criterion	Rationale for exclusion	
PM3 For recessive disorders, detected in trans	Not relevant because LFS is not a recessive disorder, but	
with a pathogenic variant.	rather a dominant disorder.	
PM4 Protein length changes as a result of in-		
frame deletions/insertions in a nonrepeat region	Not used due to limited available data.	
or stop-loss variants.		
PP2 Missense variant in a gene that has a low rate	Not applicable due to the high rate of benign missense	
of benign missense variation and where missense	variation in <i>TP53</i> .	
variants are a common mechanism of disease		
PP4 Patient's phenotype or family history is	Already captured by the specifications of PS4, and thus	
highly specific for a disease with a single genetic	cannot be used as independent evidence.	
etiology.	1	
PP5 Reputable source recently reports variant as	Not applicable following Sequence Variant	
pathogenic, but the evidence is not available to the laboratory to perform an independent	Interpretation recommendations (Biesecker & Harrison,	
evaluation.	2018).	
BP1 Missense variant in a gene for which	Not relevant, as truncating variants account for only a	
primarily truncating variants are known to cause	portion of disease-causing variants in <i>TP53</i> and there	
disease.	are many pathogenic missense alleles.	
BP3 In-frame deletions/insertions in a repetitive		
region without a known function.	Not used due to limited available data	
	Not used at this time as an individual could have	
BP5 Variant found in a case with an alternate	multiple hereditary factors to explain a personal and/or	
molecular basis for disease.	family history of cancer. Therefore, having a known	
molecular basis for disease.	ATM pathogenic variant would not eliminate the	
	possibility of also having a TP53 pathogenic variant.	
BP6 Reputable source recently reports variant as	Not applicable following Sequence Variant	
benign, but the evidence is not available to the	Interpretation recommendations (Biesecker & Harrison,	
laboratory to perform an independent evaluation.	2018).	

Clinical criteria		Non-carriers	Risk Ratio	RR 95%-CI
Classic LFS Chompret 2015	4 298 64 298			15.57 [1.75; 138.79] 3.37 [2.47; 4.59]

Supplementary Figure 1. Calculation of likelihood ratios of pathogenicity for a variant found in a proband meeting Classic LFS or only Chompret 2015 clinical criteria, using data from Ambry Genetics, where events corresponds to the number of *TP53* carriers or non-carriers meeting each of these clinical criteria

Supplementary Table 2. Likelihood ratios (LR) towards pathogenicity for a variant identified in a female individual with no cancer by age 60 for the specification of the BS2 criterion, using data from Ambry Genetics and GeneDx

Dataset	Ambry Genetics			GeneDx		
Individuals with no cancer by	% <i>TP53</i> carriers (n/total N)	% Non- carriers (n/total N)	LR (95% CI)	% TP53 carriers (n/total N)	% Non- carriers (n/total N)	LR (95% CI)
age 60 (n)	12.38	18.62	0.66 (0.48;	5.63	19.97 (18936/	0.28 (0.14;
	(38/307)	(210/112)	0.92)	(8/142)	94807)	0.55)

Supplementary Table 3. Likelihood ratios (LR) towards pathogenicity estimated for the original ACMG/AMP PM5 criterion, based on amino acid (aa) residues observations of 493 non-functional and 1239 functional or supertrans variants from yeast transactivation assays

Number of occurrences of an aa in the dataset	Number of pathogenic variants at that aa	%	Number of benign variants at the same aa	%	LR (95% CI)
1	55	11.16	159	12.83	0.87 (0.66, 1.15)
2	52	10.55	45	3.63	2.90 (1.99, 4.24)
3	72	14.60	28	2.26	6.46 (4.26, 9.80)
4	72	14.60	10	0.81	18.09 (9.46, 34.61)
5	145	29.41	10	0.81	36.44 (19.46, 68.25)
6 or more	97	19.7	0.00	0.00	NA

Supplementary Table 4. Comparison of performance of functional assays against reference sets of assumed pathogenic and benign p53 missense variants based on clinical evidence

Given name to the functional assay	Matthews correlation coefficient
Kato LOF	0.94
Giacomelli LOF (etoposide) + DNE	0.88
Kotler LOF	0.77
Giacomelli LOF (etoposide)	0.73
Giacomelli DNE (etoposide)	0.70
Giacomelli LOF (nutlin)	0.34